Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 44

1.

Balixafortide plus eribulin in HER2-negative metastatic breast cancer: a phase 1, single-arm, dose-escalation trial.

Pernas S, Martin M, Kaufman PA, Gil-Martin M, Gomez Pardo P, Lopez-Tarruella S, Manso L, Ciruelos E, Perez-Fidalgo JA, Hernando C, Ademuyiwa FO, Weilbaecher K, Mayer I, Pluard TJ, Martinez Garcia M, Vahdat L, Perez-Garcia J, Wach A, Barker D, Fung S, Romagnoli B, Cortes J.

Lancet Oncol. 2018 Apr 26. pii: S1470-2045(18)30147-5. doi: 10.1016/S1470-2045(18)30147-5. [Epub ahead of print]

PMID:
29706375
2.

ER+ Breast Cancers Resistant to Prolonged Neoadjuvant Letrozole Exhibit an E2F4 Transcriptional Program Sensitive to CDK4/6 Inhibitors.

Guerrero-Zotano AL, Stricker TP, Formisano L, Hutchinson KE, Stover DG, Lee KM, Schwarz LJ, Giltnane JM, Estrada MV, Jansen VM, Servetto A, Gavilá J, Perez-Fidalgo JA, Lluch A, Llombart-Cussac A, Bayar MA, Michiels S, André F, Arnedos M, Guillem V, Ruiz-Simon A, Arteaga CL.

Clin Cancer Res. 2018 Mar 26. doi: 10.1158/1078-0432.CCR-17-2904. [Epub ahead of print]

PMID:
29581135
3.

A Phase I Open-Label Study to Identify a Dosing Regimen of the Pan-AKT Inhibitor AZD5363 for Evaluation in Solid Tumors and in PIK3CA-Mutated Breast and Gynecologic Cancers.

Banerji U, Dean EJ, Pérez-Fidalgo JA, Batist G, Bedard PL, You B, Westin SN, Kabos P, Garrett MD, Tall M, Ambrose H, Barrett JC, Carr TH, Cheung SYA, Corcoran C, Cullberg M, Davies BR, de Bruin EC, Elvin P, Foxley A, Lawrence P, Lindemann JPO, Maudsley R, Pass M, Rowlands V, Rugman P, Schiavon G, Yates J, Schellens JHM.

Clin Cancer Res. 2018 May 1;24(9):2050-2059. doi: 10.1158/1078-0432.CCR-17-2260. Epub 2017 Oct 24.

PMID:
29066505
4.

MYC and MCL1 Cooperatively Promote Chemotherapy-Resistant Breast Cancer Stem Cells via Regulation of Mitochondrial Oxidative Phosphorylation.

Lee KM, Giltnane JM, Balko JM, Schwarz LJ, Guerrero-Zotano AL, Hutchinson KE, Nixon MJ, Estrada MV, Sánchez V, Sanders ME, Lee T, Gómez H, Lluch A, Pérez-Fidalgo JA, Wolf MM, Andrejeva G, Rathmell JC, Fesik SW, Arteaga CL.

Cell Metab. 2017 Oct 3;26(4):633-647.e7. doi: 10.1016/j.cmet.2017.09.009.

PMID:
28978427
5.

AKT Inhibition in Solid Tumors With AKT1 Mutations.

Hyman DM, Smyth LM, Donoghue MTA, Westin SN, Bedard PL, Dean EJ, Bando H, El-Khoueiry AB, Pérez-Fidalgo JA, Mita A, Schellens JHM, Chang MT, Reichel JB, Bouvier N, Selcuklu SD, Soumerai TE, Torrisi J, Erinjeri JP, Ambrose H, Barrett JC, Dougherty B, Foxley A, Lindemann JPO, McEwen R, Pass M, Schiavon G, Berger MF, Chandarlapaty S, Solit DB, Banerji U, Baselga J, Taylor BS.

J Clin Oncol. 2017 Jul 10;35(20):2251-2259. doi: 10.1200/JCO.2017.73.0143. Epub 2017 May 10.

PMID:
28489509
6.

A First-in-Human Phase I Study of the ATP-Competitive AKT Inhibitor Ipatasertib Demonstrates Robust and Safe Targeting of AKT in Patients with Solid Tumors.

Saura C, Roda D, Roselló S, Oliveira M, Macarulla T, Pérez-Fidalgo JA, Morales-Barrera R, Sanchis-García JM, Musib L, Budha N, Zhu J, Nannini M, Chan WY, Sanabria Bohórquez SM, Meng RD, Lin K, Yan Y, Patel P, Baselga J, Tabernero J, Cervantes A.

Cancer Discov. 2017 Jan;7(1):102-113. doi: 10.1158/2159-8290.CD-16-0512. Epub 2016 Nov 21.

7.

Clinical implications of routine genomic mutation sequencing in PIK3CA/AKT1 and KRAS/NRAS/BRAF in metastatic breast cancer.

Cejalvo JM, Pérez-Fidalgo JA, Ribas G, Burgués O, Mongort C, Alonso E, Ibarrola-Villava M, Bermejo B, Martínez MT, Cervantes A, Lluch A.

Breast Cancer Res Treat. 2016 Nov;160(1):69-77. Epub 2016 Sep 14.

PMID:
27628192
8.

Determination of somatic oncogenic mutations linked to target-based therapies using MassARRAY technology.

Ibarrola-Villava M, Fleitas T, Llorca-Cardeñosa MJ, Mongort C, Alonso E, Navarro S, Burgues O, Vivancos A, Cejalvo JM, Perez-Fidalgo JA, Roselló S, Ribas G, Cervantes A.

Oncotarget. 2016 Apr 19;7(16):22543-55. doi: 10.18632/oncotarget.8002.

9.

Deregulation of ARID1A, CDH1, cMET and PIK3CA and target-related microRNA expression in gastric cancer.

Ibarrola-Villava M, Llorca-Cardeñosa MJ, Tarazona N, Mongort C, Fleitas T, Perez-Fidalgo JA, Roselló S, Navarro S, Ribas G, Cervantes A.

Oncotarget. 2015 Sep 29;6(29):26935-45. doi: 10.18632/oncotarget.4775.

10.

Treatment of HER2 positive advanced breast cancer with T-DM1: A review of the literature.

Martínez MT, Pérez-Fidalgo JA, Martín-Martorell P, Cejalvo JM, Pons V, Bermejo B, Martín M, Albanell J, Lluch A.

Crit Rev Oncol Hematol. 2016 Jan;97:96-106. doi: 10.1016/j.critrevonc.2015.08.011. Epub 2015 Aug 11. Review.

PMID:
26318092
11.

EGF-Induced Acetylation of Heterogeneous Nuclear Ribonucleoproteins Is Dependent on KRAS Mutational Status in Colorectal Cancer Cells.

Roda D, Castillo J, Telechea-Fernández M, Gil A, López-Rodas G, Franco L, González-Rodríguez P, Roselló S, Pérez-Fidalgo JA, García-Trevijano ER, Cervantes A, Zaragozá R.

PLoS One. 2015 Jun 25;10(6):e0130543. doi: 10.1371/journal.pone.0130543. eCollection 2015.

12.

Primary paraesophageal Ewing's sarcoma: an uncommon case report and literature review.

Tarazona N, Navarro L, Cejalvo JM, Gambardella V, Pérez-Fidalgo JA, Sempere A, Navarro S, Cervantes A.

Onco Targets Ther. 2015 May 14;8:1053-9. doi: 10.2147/OTT.S80879. eCollection 2015.

13.

MicroRNA profile in very young women with breast cancer.

Peña-Chilet M, Martínez MT, Pérez-Fidalgo JA, Peiró-Chova L, Oltra SS, Tormo E, Alonso-Yuste E, Martinez-Delgado B, Eroles P, Climent J, Burgués O, Ferrer-Lozano J, Bosch A, Lluch A, Ribas G.

BMC Cancer. 2014 Jul 21;14:529. doi: 10.1186/1471-2407-14-529.

14.

Emerging EGFR antagonists for breast cancer.

Lluch A, Eroles P, Perez-Fidalgo JA.

Expert Opin Emerg Drugs. 2014 Jun;19(2):165-81. doi: 10.1517/14728214.2014.903919. Epub 2014 May 15. Review.

PMID:
24831079
15.

Subcutaneous trastuzumab: drug development and current position.

Martín Martorell P, Bermejo de Las Heras B, Pérez-Fidalgo JA, Huerta Alvaro M, Martín M, Albanell J, Lluch Hernández A.

Clin Transl Oncol. 2014 Oct;16(10):859-64. doi: 10.1007/s12094-014-1181-y. Epub 2014 Apr 29. Review.

PMID:
24777594
16.

Concordance of genomic alterations between primary and recurrent breast cancer.

Meric-Bernstam F, Frampton GM, Ferrer-Lozano J, Yelensky R, Pérez-Fidalgo JA, Wang Y, Palmer GA, Ross JS, Miller VA, Su X, Eroles P, Barrera JA, Burgues O, Lluch AM, Zheng X, Sahin A, Stephens PJ, Mills GB, Cronin MT, Gonzalez-Angulo AM.

Mol Cancer Ther. 2014 May;13(5):1382-9. doi: 10.1158/1535-7163.MCT-13-0482. Epub 2014 Mar 7.

17.

Retrospective analysis of the use of G-CSF and its impact on dose response for anthracycline plus taxane-based schedules in early breast cancer.

Pérez-Fidalgo JA, Bermejo B, Chirivella I, Martínez MT, González I, Cejalvo JM, Catoira I, Martínez P, Contel E, Lluch A.

Clin Transl Oncol. 2014 Sep;16(9):814-22. doi: 10.1007/s12094-013-1153-7. Epub 2014 Feb 15.

18.

Quality-of-Life assessment in malignant pleural effusion treated with indwelling pleural catheter: a prospective study.

Lorenzo MJ, Modesto M, Pérez J, Bollo E, Cordovilla R, Muñoz M, Pérez-Fidalgo JA, Cases E.

Palliat Med. 2014 Apr;28(4):326-34. doi: 10.1177/0269216314521851. Epub 2014 Feb 12.

PMID:
24523284
19.

Emergence of constitutively active estrogen receptor-α mutations in pretreated advanced estrogen receptor-positive breast cancer.

Jeselsohn R, Yelensky R, Buchwalter G, Frampton G, Meric-Bernstam F, Gonzalez-Angulo AM, Ferrer-Lozano J, Perez-Fidalgo JA, Cristofanilli M, Gómez H, Arteaga CL, Giltnane J, Balko JM, Cronin MT, Jarosz M, Sun J, Hawryluk M, Lipson D, Otto G, Ross JS, Dvir A, Soussan-Gutman L, Wolf I, Rubinek T, Gilmore L, Schnitt S, Come SE, Pusztai L, Stephens P, Brown M, Miller VA.

Clin Cancer Res. 2014 Apr 1;20(7):1757-1767. doi: 10.1158/1078-0432.CCR-13-2332. Epub 2014 Jan 7.

20.

Zoledronic acid in the treatment of metastatic breast cancer.

Lluch A, Cueva J, Ruiz-Borrego M, Ponce J, Pérez-Fidalgo JA.

Anticancer Drugs. 2014 Jan;25(1):1-7. doi: 10.1097/CAD.0000000000000020. Review.

PMID:
24100278
21.

An evaluation of the impact of technical bias on the concordance rate between primary and recurrent tumors in breast cancer.

Pérez-Fidalgo JA, Eroles P, Ferrer J, Bosch A, Burgués O, Martínez F, Bermejo B, Lluch A, González-Angulo AM.

Breast. 2013 Oct;22(5):974-9. doi: 10.1016/j.breast.2013.05.014. Epub 2013 Jun 25.

PMID:
23809906
22.

Reply to 'Comment on: management of chemotherapy extravasation: ESMO-EONS clinical practice guidelines'.

Pérez-Fidalgo JA, Cervantes A.

Ann Oncol. 2013 Apr;24(4):1129-30. doi: 10.1093/annonc/mdt024. Epub 2013 Feb 13. No abstract available.

PMID:
23406727
23.

Management of chemotherapy extravasation: ESMO--EONS clinical practice guidelines.

Pérez Fidalgo JA, García Fabregat L, Cervantes A, Margulies A, Vidall C, Roila F; ESMO Guidelines Working Group.

Eur J Oncol Nurs. 2012 Dec;16(5):528-34. No abstract available.

PMID:
23304728
24.

Management of chemotherapy extravasation: ESMO-EONS Clinical Practice Guidelines.

Pérez Fidalgo JA, García Fabregat L, Cervantes A, Margulies A, Vidall C, Roila F; ESMO Guidelines Working Group.

Ann Oncol. 2012 Oct;23 Suppl 7:vii167-73. No abstract available.

PMID:
22997449
25.

Current questions for the treatment of advanced gastric cancer.

Cervantes A, Roda D, Tarazona N, Roselló S, Pérez-Fidalgo JA.

Cancer Treat Rev. 2013 Feb;39(1):60-7. doi: 10.1016/j.ctrv.2012.09.007. Epub 2012 Oct 25. Review.

PMID:
23102520
26.

Phase I pharmacokinetic/pharmacodynamic study of MLN8237, an investigational, oral, selective aurora a kinase inhibitor, in patients with advanced solid tumors.

Cervantes A, Elez E, Roda D, Ecsedy J, Macarulla T, Venkatakrishnan K, Roselló S, Andreu J, Jung J, Sanchis-Garcia JM, Piera A, Blasco I, Maños L, Pérez-Fidalgo JA, Fingert H, Baselga J, Tabernero J.

Clin Cancer Res. 2012 Sep 1;18(17):4764-74. doi: 10.1158/1078-0432.CCR-12-0571. Epub 2012 Jul 2.

27.

Integrating radical local treatment of the primary in the management of stage IV breast cancer. When is the best moment for the resection of the primary tumor?

Perez-Fidalgo JA, Caballero A, Lluch A.

Eur J Surg Oncol. 2012 Aug;38(8):643-4. doi: 10.1016/j.ejso.2012.03.003. Epub 2012 Apr 5. No abstract available.

PMID:
22483703
28.

Molecular biology in breast cancer: intrinsic subtypes and signaling pathways.

Eroles P, Bosch A, Pérez-Fidalgo JA, Lluch A.

Cancer Treat Rev. 2012 Oct;38(6):698-707. doi: 10.1016/j.ctrv.2011.11.005. Epub 2011 Dec 16. Review.

PMID:
22178455
29.

Removal of primary tumor improves survival in metastatic breast cancer. Does timing of surgery influence outcomes?

Pérez-Fidalgo JA, Pimentel P, Caballero A, Bermejo B, Barrera JA, Burgues O, Martinez-Ruiz F, Chirivella I, Bosch A, Martínez-Agulló A, Lluch A.

Breast. 2011 Dec;20(6):548-54. doi: 10.1016/j.breast.2011.06.005. Epub 2011 Aug 3.

PMID:
21816613
30.

Treatment of cervical cancer: the importance of a multidisciplinary team approach.

Pérez Fidalgo JA, Hernández Machancoses A, Martín González V, Cervantes A.

Clin Transl Oncol. 2011 Jul;13(7):431-3. doi: 10.1007/s12094-011-0678-x. No abstract available.

PMID:
21775268
31.

Aurora kinase inhibitors: a new class of drugs targeting the regulatory mitotic system.

Pérez Fidalgo JA, Roda D, Roselló S, Rodríguez-Braun E, Cervantes A.

Clin Transl Oncol. 2009 Dec;11(12):787-98. Review.

PMID:
20045785
32.

Incidence of chemotherapy-induced amenorrhea in hormone-sensitive breast cancer patients: the impact of addition of taxanes to anthracycline-based regimens.

Pérez-Fidalgo JA, Roselló S, García-Garré E, Jordá E, Martín-Martorell P, Bermejo B, Chirivella I, Guzman C, Lluch A.

Breast Cancer Res Treat. 2010 Feb;120(1):245-51. doi: 10.1007/s10549-009-0426-x. Epub 2009 Jul 3.

PMID:
19575291
33.

Impact of a mammography screening programme on the breast cancer population of the Region of Valencia (Spain).

Pérez-Fidalgo JA, Miranda J, Chirivella I, Ibáñez J, Bermejo B, Pons C, Melchor I, Santaballa A, Martínez-Ruiz F, Lluch A, Salas D.

Clin Transl Oncol. 2008 Nov;10(11):745-52.

PMID:
19015071
34.

[Breast cancer metastases in the iris: does treatment modifies natural history of the illness?].

Pérez-Fidalgo JA, Vila Arteaga J, Chirivella González I, Martínez Belda R, Bermejo de Lasheras B, Roselló Keranën S, Fons Moreno A, Lluch Hernández A.

An Med Interna. 2008 Apr;25(4):178-80. Spanish.

35.

[Hyperammonaemic encephalopathy, possible complication after urinary diversion in radical cystectomy. Review of the literature with regard to a clinical case].

Pérez-Fidalgo JA, Chirivella González I, Günthner S, Cervera Miguel JI, March Villalba JA, Cervantes Ruipérez A.

Actas Urol Esp. 2007 Apr;31(4):394-9. Review. Spanish.

PMID:
17633926
36.

Parotid gland metastasis of a breast cancer.

Perez-Fidalgo JA, Chirivella I, Laforga J, Colio JM, Blanes MD, Baydal R, Roselló S, De-la-Morena E, Lluch A.

Clin Transl Oncol. 2007 Apr;9(4):264-5.

PMID:
17462982
37.

Primary carcinoid tumour of the pancreas.

Pérez-Fidalgo JA, Oltra Ferrando A, López Jiménez A, Maestu Maiques I.

Clin Transl Oncol. 2006 Jan;8(1):54-6.

PMID:
16632441
38.

Carboplatin and tegafur-uracil concomitant with standard radiotherapy in the management of locally advanced head and neck cancer.

Segura Huerta A, Díaz-Beveridge R, Pérez-Fidalgo JA, Calderero Aragón V, Pastor Borgoñón M, Aparicio Urtasun J, Montalar Salcedo J.

Clin Transl Oncol. 2005 Jan-Feb;7(1):23-8.

PMID:
15890152
39.

[Non-Hodgkin lymphomas with systemic presentation in patients with HIV infection. Clinical and prognostic factors in a series evaluated before the introduction of the highly active antiretroviral therapy (HAART)].

Segura Huerta A, López Tendero P, Romera Barroso B, Yuste Izquierdo AL, Gironés Sarrió R, Pérez Fidalgo JA, Gómez Codina J, López Aldeguer J.

Rev Clin Esp. 2004 Jun;204(6):303-7. Spanish.

PMID:
15171891
40.

[Thirteen years' survival in a patient with isolated skin metastases of a gastric carcinoma. What kind of disease is that?].

Segura Huerta A, Pérez-Fidalgo JA, López-Tendero P, Gironés Sarrió R, Aparicio Urtasun J.

An Med Interna. 2003 May;20(5):251-3. Spanish.

PMID:
12831300
41.

Analysis of clinical prognostic factors for survival and time to progression in patients with metastatic colorectal cancer treated with 5-fluorouracil-based chemotherapy.

Yuste AL, Aparicio J, Segura A, López-Tendero P, Gironés R, Pérez-Fidalgo JA, Díaz R, Calderero V.

Clin Colorectal Cancer. 2003 Feb;2(4):231-4.

PMID:
12620142
42.

Non-Hodgkin's lymphoma in older people: age is not always an adverse prognostic factor.

Huerta AS, Gómez-Codina J, Pastor M, Gironés R, Pérez-Fidalgo JA, Díaz R.

J Am Geriatr Soc. 2002 Nov;50(11):1911-2. No abstract available.

PMID:
12410921
43.

Pulmonary fibrosis induced by cyclophosphamide.

Segura A, Yuste A, Cercos A, López-Tendero P, Gironés R, Pérez-Fidalgo JA, Herranz C.

Ann Pharmacother. 2001 Jul-Aug;35(7-8):894-7.

PMID:
11485142
44.

[Embryonal rhabdomyosarcoma of the prostate. Report of a case and review of the literature].

Segura Huerta A, López Tendero P, Yuste Izquierdo A, Gironés Sarrió R, Pérez Fidalgo J, Aparicio Urtasun J.

Actas Urol Esp. 2001 Feb;25(2):144-9. Spanish.

PMID:
11345801

Supplemental Content

Loading ...
Support Center